Promising effects of adenosine triphosphate infusion on nutritional status and quality of life in advanced non-small-cell lung cancer: A randomized clinical trial

Drug Development Research

Volumn 59, Issue 1, 2003, Pages 146-151

  Dagnelie, Pieter C ^a   Agteresch, Hendrik J ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; C REACTIVE PROTEIN;

BODY COMPOSITION; BODY FAT; BODY WEIGHT; CALORIC INTAKE; CANCER STAGING; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INFUSION; FATIGUE; FUNCTIONAL ASSESSMENT; HUMAN; HYPERPNEA; LUNG NON SMALL CELL CANCER; MUSCLE STRENGTH; NUTRITIONAL STATUS; PHYSICAL CAPACITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THORAX DISEASE;

EID: 0038312026     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10172     Document Type: Conference Paper

References (40)

1. Agteresch HJ, et al. 2000a. Randomized clinical trial of adenosine 5′-triphosphate in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92:321-328.
2. Agteresch HJ, et al. 2000b. Pharmacokinetics of intravenous ATP in cancer patients. Eur J Clin Pharmacol 56:49-55.
3. Agteresch HJ, et al. 2002. Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: a randomized clinical trial. J Clin Oncol 20:371-378.
4. Bruera E, et al. 1985. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 69:751-754.
5. Bruera E, et al. 1990. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 66:1279-1282.
6. Chlebowski RT, et al. 1986. Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer. Cancer 58:183-186.
7. Chlebowski RT, et al. 1996. Recent implications of weight loss in lung cancer management. Nutrition 12(suppl):S43-S47.
8. Cronstein BN, Bouma MG, Becker BF. 1996. Purinergic mechanisms in inflammation. Drug Dev Res 39:426-435.
9. Dagnelie PC, et al. 1994. Effect of fish oil on cancer cachexia and host liver metabolism in rats with prostate tumors. Lipids 29:195-203.
10. Dagnelie PC, et al. 1999. Abnormal liver metabolism in cancer patients detected by 31P MR spectroscopy and stable isotope tracers. NMR Biomed 12:535-544.
11. de Haes JCM, et al. 1996. The Rotterdam Symptom Checklist (RSCL): a manual, ed. N.C.f.H.C. Research. 1-38.
12. Dewys WD, et al. 1980. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69:491-497.
13. Diggle PJ, Linang KY, Zeger SL. 1994. Analysis of longitudinal data. Oxford: Clarendon Press.
14. Di Virgilio F, et al. 1998. Purinergic P2X7 receptor: a pivotal role in inflammation and immunomodulation. Drug Dev Res 45:207-213.
15. Drott C, Persson H, Lundholm K. 1989. Cardiovascular and metabolic response to adrenaline infusion in weight-losing patients with and without cancer. Clin Physiol 9:427-439.
16. Durnin JV, Womersley J. 1974. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr 32:77-97.
17. Feliu J, et al. 1992. Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo-controlled study. Am J Clin Oncol 15:436-440.
18. Firestein GS. 1996. Anti-inflammatory effects of adenosine kinase inhibitors in acute and chronic inflammation. Drug Dev Res 39:371-376.
19. Goldberg RM, et al. 1995. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo- controlled trial. J Clin Oncol 13:2856-2859.
20. Gurney JM, Jelliffe DB. 1973. Arm anthropometry in nutritional assessment: nomogram for rapid calculation of muscle circumference and cross-sectional muscle and fat areas. Am J Clin Nutr 26:912-915.
21. Haskell CM, et al. 1996. Phase I trial of extracellular adenosine 5′-triphosphate in patients with advanced cancer. Med Pediatr Oncol 27:165-173.
22. Haskell CM, et al. 1998. Phase II study of intravenous adenosine 5′-triphosphate in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer. Invest New Drugs 16:81-85.
23. Kardinal CG, et al. 1990. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 65:2657-2662.
24. Loprinzi CL, et al. 1993. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 11:762-767.
25. Loprinzi CL, et al. 1994. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer, J Clin Oncol 12:1126-1129.
26. Lundholm K, et al. 1976. Skeletal muscle metabolism in patients with malignant tumor. Eur J Cancer 12:465-473.
27. Leij-Halfwerk S, et al. 2002. Adenosine triphosphate infusion increases liver energy status in advanced lung cancer patients: an in vivo 31P magnetic resonance spectroscopy study. Hepatology 35:421-424.
28. Leij-Halfwerk S, et al. 2002a. Weight loss and elevated gluconeogenesis from alanine in lung cancer patients. Am J Clin Nutr 71:583-589.
29. Leij-Halfwerk S, et al. 2002b. Altered hepatic gluconeogenesis during L-alanine infusion in weight-losing lung cancer patients as observed by phosphorus magnetic resonance spectroscopy and turnover measurements. Cancer Res 60:618-623.
30. Lundholm K, et al. 1982. Glucose turnover, gluconeogenesis from glycerol, and estimation of net glucose cycling in cancer patients. Cancer 50:1142-1150.
31. McPherson JA, et al. 2001. Adenosine A(2A) receptor stimulation reduces inflammation and neointimal growth in a murine carotid ligation model. Arterioscler Thromb Vasc Biol 21:791-796.
32. Nixon DW, et al. 1980. Protein-calorie undernutrition in hospitalized cancer patients. Am J Med 68:683-690.
33. Ovesen L, et al. 1993. Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J Clin Oncol 11:2043-2049.
34. Popiela T, Lucchi R, Giongo F. 1989. Methylprednisolone as palliative therapy for female terminal cancer patients. The Methylprednisolone Female Preterminal Cancer Study Group. Eur J Cancer Clin Oncol 25:1823-1829.
35. Rapaport E. 1988. Experimental cancer therapy in mice by adenine nucleotides. Eur J Cancer Clin Oncol 24:1491-1497.
36. Schneeberger AL, et al. 1989. Effect of cancer on the in vivo energy state of rat liver and skeletal muscle. Cancer Res 49:1160-1164.
37. Shapot VS, Blinov VA. 1974. Blood glucose levels and gluconeogenesis in animals bearing transplantable tumors. Cancer Res 34:1827-1832.
38. Shaw JH, Wolfe RR. 1987. Fatty acid and glycerol kinetics in septic patients and in patients with gastrointestinal cancer. The response to glucose infusion and parenteral feeding. Ann Surg 205:368-376.
39. Simons JP, et al. 1998. Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial. Cancer 82:553-560.
40. van Eys J. 1982. Effect of nutritional status on responses to therapy. Cancer Res 42(suppl):747s-753s.